Dr. Sarah A. Buckley to be recognized as the inaugural Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care recipient during the JP Morgan Healthcare Conference 2018
Lugano, Switzerland, January 8, 2018 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO), are delighted to recognize Dr Sarah A. Buckley, MD, of the University of Washington as the first recipient of the Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care at the Helsinn reception held during the JP Morgan Healthcare Conference 2018. Dr. Buckley received the award at the 2017 ASCO Annual Meeting in Chicago. A new recipient for the grant will be named in June.
The YIA is a $50,000 grant for physicians who are in their final years of training to aid their transition from a fellowship program to a faculty appointment, with an aim to promote quality research in clinical oncology. Dr. Buckley is a senior fellow in hematology/oncology with a particular clinical interest in developing tools to improve medical decision-making for patients with aggressive myeloid malignancies. She is currently in the process of developing an acute myeloid leukemia-specific (AML) quality of life instrument.
The endowed YIA honours the life of Anna Braglia, the wife of Helsinn Group Founder and Chairman Gabriele Braglia and mother of Helsinn Group Vice Chairman and CEO Riccardo Braglia. Helsinn endowed this award, which is part of Conquer Cancer’s Grants and Award’s Program, to encourage more aspiring physicians by supporting them as they move from academia into research to seek advances in all areas of oncology.
Helsinn is proud to showcase its strong commitment to support the Conquer Cancer by hosting an evening reception where Dr Buckley’s award will be celebrated.
Helsinn will make a $25 donation to the Conquer Cancer on behalf of every guest who attends the reception.
Helsinn Cocktail Reception at JP Morgan 2018
|Date||Tuesday, January 9, 2018|
|Time||6:30 PM—9:30 PM|
|Location||The Marker San Francisco 501 Geary Street San Francisco, CA 94102|
Riccardo Braglia, Helsinn Group Vice Chairman and CEO, commented: “Dr. Sarah Buckley is an outstanding recipient of this award as her work holds the potential to radically improve our understanding of the support needed by patients with AML. Guided by our solid values of respect, integrity and quality, our passion-driven mission is to keep the cancer patient at the heart of everything we do. Helsinn is committed to helping people with cancer improve their quality of life. Dr. Buckley’s work is highly complementary to this goal. We are delighted to honor her with the Anna Braglia Endowed Young Investigator Award at an event dedicated to areas of research such as this, which can have such a significant impact on the lives of people with cancer.”
“Donor-supported research fuels the breakthroughs all patients need. We are grateful and honoured that Helsinn has committed to sustain the work of young researchers like Dr.Buckley” says Nancy R. Daly, MS, MPH, Conquer Cancer’s Executive Vice President and Chief Philanthropic Officer. The generous promise Helsinn made by endowing the Anna Braglia Endowed Young Investigator Award ensures decades of important work to help conquer cancer.
About the Helsinn Group
Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. Since 2012, Helsinn has been coordinating clinical and regulatory activities in China from Beijing and in 2017 established an office in Shanghai to pursue commercial activities. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, and the U.S., as well as a product presence in approximately 190 countries globally.
About Conquer Cancer
Conquer Cancer Foundation raises money to support research for all patients with cancer, everywhere. In 1964, seven oncologists created the American Society of Clinical Oncology (ASCO), now a global network of more than 40,000 cancer professionals. As ASCO’s foundation, Conquer Cancer raises funds to support scientists who are uncovering new treatments across all cancers, sharing cutting-edge knowledge, launching clinical trials, and turning science into a sigh of relief for patients in need of life-saving therapies. For more information, visit CONQUER.ORG.
For more information:
Helsinn Group Media Contact:
Group Head of Communication
Tel: +41 (0) 91 985 21 21